Surviving and thriving after a transplant

The crucial role of nursing in
improving VOD outcomes

27th January 2022 | 4:00pm - 6:00pm

Jazz promotional and educational meeting
CPD accreditation has been applied for this meeting

Topics covered include:

  • VOD pathophysiology and clinical presentation
  • Identifying and monitoring at-risk VOD patients
  • Key actions nurses can take to improve patient outcomes

UK-DEF-2100129 | November 2021

PI and AE reporting can be found at the top of the page

Learn more about best practice in severe VOD identification and treatment

Help patients survive and thrive after a transplant.

This treatment journey is designed by Jazz Pharmaceuticals for illustrative purposes.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at: https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at: AEreporting@jazzpharma.com

Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.